Скачать с ютуб Suramin Reduces Drug Resistance In Mycobacteria Says RGCB || Hybiz tv в хорошем качестве

Suramin Reduces Drug Resistance In Mycobacteria Says RGCB || Hybiz tv

A family of harmful bacteria that causes diseases like TB and leprosy has become increasingly resistant to antibiotics, and the alarming situation warrants novel strategies to control evolution of drug resistance in mycobacteria, says a study by Dr. Krishna Kurthkoti, a scientist and researcher at Rajiv Gandhi Centre for Biotechnology (RGCB). The study, published in Antimicrobial agents and chemotherapy, reveals that application of antibiotics results in a two-phase killing of bacteria, with a significant part of the population being killed rapidly while a smaller sub-population of bacteria called ‘persister’ endures the antibiotic and persist in the environment for extended periods.The persisters also get killed because they remain susceptible to antibiotics, but the killing rate is much slower. Non-compliance with the duration of antibiotic therapy results in a relapse of infection caused by the persisters.Recent reports also suggest that antibiotic persisters (APs) of mycobacteria develop resistance upon treatment with lethal doses of ciprofloxacin or rifampicin.The research conducted in the laboratory of Dr Krishna demonstrated that the persister population of M. smegmatis generated by antibiotic treatment showed high levels of reactive oxygen species (ROS), which consequently resulted in the rapid emergence of drug resistance to single and multiple antibiotics.Strategies to tackle drug-resistant strains include identification of new antibiotics or targeting the bacterial mechanisms that reduce the rate of evolution of resistance. The study tested the efficacy of Suramin, a WHO-approved drug used for treating Trypanasomal (sleeping sickness and river blindness) infections. It showed that a combination of Suramin during antibiotic therapy reduced the emergence rate of drug resistance in M. smegmatis and M. tuberculosis under laboratory conditions. Since Suramin is already an approved drug, its repurposing to control the emergence of drug resistance would increase the life expectancy of existing drugs providing valuable time to develop and approve new antibiotics.RGCB director Dr Chandrabhas Narayana said it is a significant study as it highlights suramin's novel application as a broad-spectrum agent in combating the development of drug resistance. It will bring into focus the need to discover new antibiotics to counter the emergence of antimicrobial resistance (AMR), which has become a major global health concern compelling the WHO to declare that the crisis needs immediate attention. #Suramin #Mycobacteria #RGCB #RajivGandhiCentrefor Biotechnology #Hybiz HyBiz Tv is India’s most watched Digital Business Channel with over One Million regular viewers. in the 12 years of its existence, HyBiz Tv has provided a platform for business houses to promote, project and propagate their products and services. Corporate videos, Promotional videos, Interviews, Ad- films, events coverage, current relevant news, meaningful discussions on contemporary subjects have given the audience relevant content which has helped in the rapid growth of the viewership. Clients from both the Telugu states and across the country have reaped rich dividends by engaging HyBiz Tv and now this has spread all over the country. ► Watch More Business Videos at India's Leading online business channel http://www.hybiz.tv ► like us on Facebook:   / hybiz   ► Watch More Videos on    / hybiztv   ► Subscribe to HYBIZTV Channel: goo.gl/EEXqfu ►Follow us on Twitter   / hybiztv